Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Carbenicillin Phenyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.70 |
| ▸ | RECQL | P46063 | 4/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | POLB | P06746 | 3/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.70 |
| ▸ | GLA | P06280 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | TEK | Q02763 | 1/20 | 0.57 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.57 |
| ▸ | FPR1 | P21462 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbenicillin Phenyl SCHEMBL192220 | 1.00 | LMNA (0.79) | LMNAKDM4ERECQLHSD17B10CYP3A4 | |
| Carbenicillin Phenyl SCHEMBL11308035 | 1.00 | LMNA (0.79) | LMNAKDM4ERECQLHSD17B10CYP3A4 | |
| Carbenicillin Phenyl SCHEMBL150615 | 0.92 | KDM4E (0.68) | LMNAKDM4ERECQLHSD17B10CYP3A4 | |
| Carbenicillin Phenyl SCHEMBL10734854 | 0.92 | KDM4E (0.68) | LMNAKDM4ERECQLHSD17B10CYP3A4 | |
| Carbenicillin Phenyl SCHEMBL11310099 | 0.92 | KDM4E (0.68) | LMNAKDM4ERECQLHSD17B10CYP3A4 | |
| Carbenicillin Phenyl SCHEMBL150616 | 0.92 | KDM4E (0.68) | LMNAKDM4ERECQLHSD17B10CYP3A4 | |
| Carbenicillin Phenyl SCHEMBL11308037 | 0.91 | KDM4E (0.67) | LMNAKDM4ERECQLHSD17B10CYP3A4 | |
| Carbenicillin Phenyl SCHEMBL11475569 | 0.91 | KDM4E (0.67) | LMNAKDM4ERECQLHSD17B10CYP3A4 | |
| Carbenicillin Phenyl SCHEMBL586468 | 0.91 | KDM4E (0.67) | LMNAKDM4ERECQLHSD17B10CYP3A4 | |
| Carbenicillin SCHEMBL11317057 | 0.88 | LMNA (0.88) | LMNAKDM4ERECQLHSD17B10CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122095251-A | Use of secreted CDCP1 for improving treatment of non-alcoholic steatohepatitis | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260127735-A1 | DEEP LEARNING ESTIMATION OF VASCULAR FLOW AND PROPERTIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260098244-A1 | DEVICES, CHROMATOGRAPHY COLUMNS, METHODS FOR AUTOMATED CHROMATOGRAPHY IN PARALLEL AND METHODS FOR PURIFICATION OF EXTRACELLULAR VESICLES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4718076-A2 | WORKFLOW FOR RISK ASSESSMENT AND PATIENT MANAGEMENT USING PROCALCITONIN AND MIDREGIONAL-PROADRENOMEDULLIN | B.R.A.H.M.S GmbH (DE) | 2026-04-01 | — | — | EP | disclosed |
| EP-3729101-B1 | WORKFLOW FOR RISK ASSESSMENT AND PATIENT MANAGEMENT USING PROCALCITONIN AND PROADRENOMEDULLIN | BRAHMS GMBH (DE) | 2026-03-18 | — | — | EP | disclosed |
| US-12578344-B2 | Compositions, kits, and methods for detecting preclinical alzheimer's disease | NEUROQUEST LTD. (IL) | 2026-03-17 | — | — | US | disclosed |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | THE CLEVELAND CLINIC FOUNDATION (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | NEW YORK UNIVERSITY (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4688864-A1 | ANTI-GALECTIN 3 ANTIBODIES AND THEIR USE IN EPILEPSY AND RELATED DISEASES | Sunmed Therapeutic Limited (HK) | 2026-02-11 | — | — | EP | disclosed |
| US-20260034233-A1 | ANTI-GALECTIN 3 ANTIBODIES AND THEIR USE IN EPILEPSY AND RELATED DISEASES | SUNMED THERAPEUTIC LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| US-11351363-B2 | Nerve stimulation devices and methods for treating cardiac arrhythmias | ELECTROCORE, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11340240-B2 | Method for predicting the risk of obesity in a subject | SPHINGOTEC GMBH (DE) | 2022-05-24 | — | — | US | disclosed |
| WO-2022104212-A1 | METHODS FOR DECREASING MORTALITY RISK AND IMPROVING HEALTH | AMGEN INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2022086913-A2 | CARDIOVASCULAR EVENT RISK PREDICTION | SOMALOGIC OPERATING CO., INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022082261-A1 | METHODS OF ASSESSING RISK OF DEVELOPING A DISEASE | GENETIC TECHNOLOGIES LIMITED (AU) | 2022-04-28 | — | — | WO | disclosed |
| CN-114402394-A | Method for predicting whether renal transplant recipient is at risk of allograft loss | 公共救济事业局-巴黎医院 | 2022-04-26 | — | — | CN | disclosed |
| US-20220049306-A1 | CARDIOVASCULAR DISEASE | GENINCODE UK, LTD. (GB) | 2022-02-17 | — | — | US | disclosed |
| WO-2022031920-A2 | END STAGE RENAL DISEASE BIOMARKER PANEL | JOSLIN DIABETES CENTER, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| US-20220040473-A1 | NERVE STIMULATION DEVICES AND METHODS FOR TREATING CARDIAC ARRHYTHMIAS | AVENUE VENTURE OPPORTUNITIES FUND II, L.P. | 2022-02-10 | — | — | US | disclosed |
| EP-3942563-A1 | METHOD OF PREDICTING WHETHER A KIDNEY TRANSPLANT RECIPIENT IS AT RISK OF HAVING ALLOGRAFT LOSS | ASSISTANCE PUBLIQUE, HOPITAUX DE PARIS (FR) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260127735-A1 | DEEP LEARNING ESTIMATION OF VASCULAR FLOW AND PROPERTIES | FLT1, FLT4, FABP3 | LMNA 1612/4885KDM4E 1572/4885RECQL 4246/4885 |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | BHMT, BHMT2, EHMT2 | LMNA 475/4885KDM4E 270/4885RECQL 4774/4885 |
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | EPB41L2, MYLK2, RABL3 | LMNA 4313/4885KDM4E 4178/4885RECQL 2572/4885 |
| US-12578344-B2 | Compositions, kits, and methods for detecting preclinical alzheimer's disease | CD59, CD209, CD47 | LMNA 1068/4885KDM4E 2496/4885RECQL 4579/4885 |
| US-20260034233-A1 | ANTI-GALECTIN 3 ANTIBODIES AND THEIR USE IN EPILEPSY AND RELATED DISEASES | LGALS3, GALR3, LGALS1 | LMNA 1215/4885KDM4E 4004/4885RECQL 4740/4885 |
| US-20260098244-A1 | DEVICES, CHROMATOGRAPHY COLUMNS, METHODS FOR AUTOMATED CHROMATOGRAPHY IN PARALLEL AND METHODS FOR PURIFICATION OF EXTRACELLULAR VESICLES | EXOSC9, EXOSC5, EXOSC4 | LMNA 1001/4885KDM4E 342/4885RECQL 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.